AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00576004 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic organ prolapse repair and Burch colposuspension
Description: Abdominal pelvic organ prolapse repair and retropubic Burch colposuspension
Study NCT01768221 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Caregiver Intervention
Description: Participants will speak with a chaplain for three brief, 45 minute to one hour, sessions.~The sessions will focus on topics of relationship life review, unresolved conflicts and issues of forgiveness, and future goals, lessons learned and legacy.~In the week following the third session, the chaplain will call participants for a brief check in. This call will include no new intervention content, rather it provides an opportunity for participants to mention any additional thoughts or concerns they want to discuss with the chaplain interventionist.
Study NCT00723697 — intervention group
Intervention type: DRUG
Intervention: buprenorphine
Description: 0.4, 2, or 8 mg sublingual tablets
Study NCT02724410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: home intravenous ertapenem
Description: see arm description
Study NCT02724410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: home oral amoxicillin-clavulanate
Description: see arm description
Study NCT02724410 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: peripheral inserted central Catheter
Description: All patients undergoing home intravenous ertapenem will require placement of peripheral inserted central Catheter (PICC) for home delivery of antibiotics.
Study NCT01063231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillCam™ (Capsule Endoscopy) Colon 2 capsule
Description: Medical Device
Study NCT04293835 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Whether to have intestinal-related disease
Description: All patients pathologically diagnosed with sigmoid or rectal cancer in Peking University Third Hospital from January 2010 to December 2018 were included in our study as the cancer group.To evaluate the relationship between the height of the sigmoid take-off and all baseline covariates in normal patients, the results of 200 patients without any intestinal-related abnormalities who underwent pelvic MRI in our center from January 2019 to June 2019 were reviewed as a normal group.
Study NCT03576352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a rapid sequence tracheostomy (RST) on rabbit cadaver
Description: The Rapid Sequence Tracheostomy (RST) consists of the following steps:~1. Orientational palpation and vertical midline skin incision followed by separation of the strap muscles~2. Exposure of the trachea and cricoid followed by anterior luxation of the trachea with a Backhaus towel clamp~3. Perform a vertical puncture with a tip scissors between the Cricoid and 1st tracheal ring followed by a vertical incision of no more than 2 rings in length.~4. An age adapted tracheal tube is inserted into the trachea and the lungs are ventilated.
Study NCT02584881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: safe opioid prescription protocol
Description: When indicated a prescription for naloxone will be given to patients discharged with prescription opioids from the trauma services. All patients will receive information on safe opioid use and storage and methods for pain management.
Study NCT04674878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: METs
Description: The isometric contraction of 7 sec will be applied followed by a stretching of 30 sec in painless range. This treatment will be given to the both sides of the neck targeting the three major accessory muscles of respiration.
Study NCT00573586 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sonablate 500 (SB-500)
Description: Sonablate 500 (SB-500)
Study NCT03502694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumicitabine
Description: Participants will receive loading dose and maintenance dose of lumicitabine tablets orally.
Study NCT03502694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo tablets orally.
Study NCT03502694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo tablets orally.
Study NCT04674878 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breathing exercise group
Description: Three exercises will be performed in a circuit, 2 circuits in every session. It will include diaphragmatic breathing exercise in which patient will be in supine position inhaling through nose and expiration through moth with half closed lips. Second exercise pursed lip breathing also in supine position with the hands on abdomen and then inspiration through nose and expiration through mouth with half closing of lips. Third exercise resisted diaphragmatic breathing also in same pattern as second exercise with an addition of 1 kg weight on abdomen.
Study NCT03789812 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual toothbrush
Description: Soft manual toothbrush (Oral B) will be used to brush occlusal, buccal and lingual teeth surfaces.
Study NCT03789812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual toothbrush
Description: Soft manual toothbrush (Oral B) will be used to brush occlusal, buccal and lingual teeth surfaces.
Study NCT03789812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric Toothbrush
Description: Electric toothbrush (Jetpik JP210) will be used to brush occlusal, buccal and lingual teeth surfaces.
Study NCT03789812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Superfloss
Description: Superfloss (Oral B) will be used to clean interproximal teeth surfaces.
Study NCT03789812 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Superfloss
Description: Superfloss (Oral B) will be used to clean interproximal teeth surfaces.
Study NCT03789812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Water Jet
Description: Dental water jet (Jetpik JP210) will be used to clean interproximal teeth surfaces.
Study NCT00470405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 75-100 mg/m2 iv infusion Approximately 2 hours beginning approximately 30 minutes after the end of ALIMTA infusion on Day 1 of a 14-days cycle
Study NCT00470405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: a novel antifolate with multiple targets.
Study NCT01558323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908
Description: Participants will receive a single oral dose of LCQ908
Study NCT02367105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: Daily testosterone gel applied once daily in the morning to intact skin
Study NCT02367105 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle Therapy
Description: Weekly behavioral diet to induce \~10% weight loss in combination with supervised aerobic and exercise training three times a week
Study NCT02367105 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Therapy
Description: Weekly behavioral diet to induce \~10% weight loss in combination with supervised aerobic and exercise training three times a week
Study NCT02367105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel for testosterone
Study NCT00974181 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conor Medsystems COSTAR™ stent (10 µg Paclitaxel)
Description: Intervention will consist of percutaneous coronary intervention for treatment of one or more de-novo coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the CoStar™ Paclitaxel-Eluting Coronary Stent System (10 µg Paclitaxel)
Study NCT04174365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Oral tablet; take once daily
Study NCT04174365 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally daily for up to Week 8.
Study NCT03084315 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: E-Cig Zero Nicotine
Description: E-Cig Zero Nicotine
Study NCT03084315 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: E-Cig 24mg Nicotine
Description: E-Cig 24mg Nicotine
Study NCT01487239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GDC-0980
Description: 100 uCi of \[14C\]-GDC-0980 in total dose of 10 mg GDC-0980
Study NCT02308371 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Pulse Pressure Variation
Description: Based on standard of care, the physician will give fluid as needed based on standard clinical data (heart rate, central venous pressure if available, blood pressure, urine output, physical exam, lactate level) and pulse pressure variation. PPV should be elevated consistently greater than 15 minutes before giving fluid without other symptoms of patient instability (low blood pressure, elevated lactate, tachycardia). Pulse pressure variation will be followed for 48 hours.
Study NCT01046357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7687
Description: Single oral dose
Study NCT01046357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral dose
Study NCT00935064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: Pill, 300 mg, once daily, for 6 weeks
Study NCT00935064 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo orally one tablet once a day for 6 weeks.
Study NCT00935064 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally one tablet once a day for 6 weeks.
Study NCT03394417 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: StrataXRT
Description: randomized patient allocated to this group will receive StrataXRT for application during the treatment and 4 weeks further after the treatment ends.
Study NCT02565199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS over Premotor Cortex (Contralateral Hemisphere)
Description: * Location of rTMS: premotor cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 50 milliseconds before the onset of movement-related EMG~* Device: MagStim Super Rapid 2 Transcranial Magnetic Stimulator
Study NCT02565199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS over Premotor Cortex (Ipsilateral Hemisphere)
Description: * Location of rTMS: premotor cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 50 milliseconds before the onset of movement-related EMG~* Device: Super Rapid 2 Transcranial Magnetic Stimulator
Study NCT02565199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS (Control 1)
Description: * Location of rTMS: premotor cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 400 milliseconds after the onset of movement-related EMG~* Device: Super Rapid 2 Transcranial Magnetic Stimulator
Study NCT02565199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS (Control 2)
Description: * Location of rTMS: somatosensory cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 50 milliseconds before the onset of movement-related EMG~* Device: Super Rapid 2 Transcranial Magnetic Stimulator
Study NCT02565199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS (Control 3)
Description: * Location of rTMS: premotor cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 50 milliseconds before the onset of movement-related EMG~* Device: Super Rapid 2 Transcranial Magnetic Stimulator with Sham Coil
Study NCT02565199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Training
Description: During motor training, participants will quickly extend their hand at a pace of one extension every 5 seconds (0.2Hz) in response to an auditory cue.
Study NCT03274362 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Headspace Mindfulness App
Description: Participants will be given instructions on how to download Headspace on an electronic device and will be provided a free 3-month access code. The app contains a series of ten step-wise 10-minute video sessions that guide the user through mindfulness training. Upon completion of these sessions, additional content will be accessible, including sessions on health (depression, self-esteem, anxiety, sleep, and pregnancy), relationships (kindness, generosity, relationships, change, appreciation, and acceptance) and performance (creativity, focus, happiness, and balance). The frequency and duration of usage will be in accordance to the instructions of the app.
Study NCT00513357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 20 mg by mouth daily for 4 Weeks
Study NCT00513357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule by mouth daily for 4 Weeks
Study NCT01147003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational new drug, company code: BGG492
Study NCT01147003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04967859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% gentamicin
Description: Patient using 0.1% gentamicin ointment at the exit site of the hemodialysis catheter
Study NCT04967859 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients using placebo ointment at the exit site of the hemodialysis catheter
Study NCT04212832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.5 ml/kg %0.25 bupivacaine
Study NCT04212832 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard pain
Description: Standard pain follow up and monitorization
Study NCT00653978 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERCP plus one biliary stent
Description: ERCP ＋ one biliary stent insertion
Study NCT00653978 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP plus two biliary stents
Description: ERCP ＋ two biliary stents insertion
Study NCT01724684 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Telehealth program
Study NCT01724684 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Study NCT02533297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Providing clinical skills conditions
Study NCT03353181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic scissors
Description: Application of endoscopic cutting technique following endoscopic nasobiliary drainage in the treatment of malignant hilar biliary strictures.
Study NCT03353181 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary stent
Description: Standard placement of biliary stent
Study NCT01417858 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: YAG laser peripheral iridotomy
Description: 1 drop 30 minutes before yag laser iridotomy
Study NCT00560911 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: educational program for the self-management of OAC
Description: Patients in the self-management group participated in 4 consecutive weekly instruction sessions of 90 to 120 minutes each, in groups of 3 to 6 patients.~After participation in the structured programme, the patients were encouraged to control their INR values by self-monitoring once a week and to adjust their anticoagulant dosage accordingly.
Study NCT00560911 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 1 hour education - afterwards physician leaded OAC control
Description: Patients in the routine control group participated a single 90-minute session~During the whole study period, they were advised with regard to changes in the anticoagulant dosage by their usual attending physicians, either in general practice or at a hospital-based specialised anticoagulation clinic.
Study NCT00550264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automatic notification of readmissions
Description: The experimental group physicians will receive automatic e-mail notification when a patient is readmitted, including contact information for the readmitting team.
Study NCT03062397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JPI-289 Low-dose
Description: JPI-289 Low dose will be intravenously administered during 24 hours
Study NCT03062397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JPI-289 High-dose
Description: JPI-289 High dose will be intravenously administered during 24 hours
Study NCT03062397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same dosage of JPI-289 Low and Hogh dose will be intravenously administered during 24 hours
Study NCT02503371 — intervention group
Intervention type: OTHER
Intervention: Blood coagulation anyalsis by Thromboelastogram
Description: Two blood tests will be taken during routine tests from all parturient s undergoing IVF treatment before starting gonadotropins treatment (the first few days of menstruation) and at the height of hormone therapy prior to egg retrieval Coagulation parameters will be measured by the use of Thromboelastogram
Study NCT03001466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: urea-loaded nanoparticles eye drops
Description: one drop five times a day for 8 weeks
Study NCT03001466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Balance Salt Solution eye drops
Description: one drop five times a day for 8 weeks
Study NCT01758159 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Study NCT01758159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CFR
Description: Complementary feeding with locally available foods according to optimized complementary feeding recommendation (CFR)
Study NCT00974181 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conor Medsystems COSTAR™ stent (30 µg Paclitaxel)
Description: Intervention will consist of percutaneous coronary intervention for treatment of one or more de-novo coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the CoStar™ Paclitaxel-Eluting Coronary Stent System (30 µg Paclitaxel)
Study NCT03613324 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pad test
Description: 20-minutes pad test and urodynamic study including uroflowmetry, filling cystometry and voiding cystometry.
Study NCT02193659 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cereals
Description: The participants were randomly single blind controlled trial distributed into three groups: (1, n =38), (2, n =38), (3, n =37). For 30 days, participants in group 1 took cereals with omega-3 in the breakfast with diet, group 2 took cereals and diet, and group 3 only received the diet.
Study NCT03286309 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: soft robot hand system
Description: subjects will wear the soft robot hand system and receive 60 minutes (including preparation time) hand exercise.
Study NCT03286309 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: soft robot hand system
Description: subjects will wear the soft robot hand system and receive 60 minutes (including preparation time) hand exercise.
Study NCT02670499 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPM
Description: Used to aid in recovery from TKR
Study NCT02670499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GAPFLEX
Description: Used to aid in the recovery of TKR
Study NCT00025506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00025506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Given orally
Study NCT01838486 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bladder Thermal Distention
Description: Bladder Thermal Distention (BTD) is an approved procedure in Europe and Israel. Continuous irrigation of the bladder with warm saline with the PelvixTT system. The procedure will be performed on an outpatients basis. The procedure lasts 1 hour.
Study NCT03567135 — intervention group
Intervention type: DRUG
Intervention: Apatinib
Description: These drugs are planned to inhibit the proliferation and metastasis of tumors.
Study NCT03567135 — intervention group
Intervention type: DRUG
Intervention: Temozolomide（TMZ）
Description: Radiotherapy is a common treatment for glioblastoma.Accompanied with TMZ, the damages caused by tumors to the normal tissues will be reduced.
Study NCT02860507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Study NCT02860507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Study NCT02860507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Study NCT04128800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib S-1
Description: apatinib 250 mg PO qd; S-1 40 mg PO in the morning and 60 mg PO in the evening; 14 days in combination, 21 days in a cycle.
Study NCT00818870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: 20 mg capsule, orally, once daily (before breakfast) for 5 days.
Study NCT00818870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vecam
Description: 1 capsule, orally, once daily at bedtime for 5 days.
Study NCT01657877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium sodium phosphosilicate
Description: CSP high percentage weight by weight
Study NCT01657877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium sodium phosphosilicate
Description: CSP high percentage weight by weight